ERYP
LISTED
EURONEXT

OTCMarkets
Ticker : EYRYY

erytech

Phase 2b Pancreatic Cancer Study
Topline Data
March 28, 2017

Disclaimer

The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma S.A., including estimates of target market opportunity, timing of planned clinical trials and results from those trials, regulatory strategy and timing of planned regulatory submissions, manufacturing capabilities and strategy for expansion of the ERYCAPS platform. Although we believe that the expectations contained in this presentation are reasonable, these forward-looking statements are only estimations based upon the information available to ERYTECH Pharma S.A. as of the date of this presentation. Except as required by law, we expressly disclaim any responsibility to publicly update or revise our forward-looking statements, whether as a result of new information, future events or otherwise. Thus, the forward-looking statements herein involve known and unknown risks and uncertainties and other important factors such that actual future operations, opportunities or financial performance may differ materially from these forward-looking statements. Undue reliance should not be placed on forward looking statements, which speak only as of the date hereof. All forward-looking statements contained herein are qualified in their entirety by the foregoing cautionary statement.

AGENDA

- Pancreatic cancer and eryaspase (GRASPA®)
- Phase 2b study design
- Topline results
- Next steps and upcoming milestones
- Q&A

Pancreatic cancer

- Approximately 150,000 new cases of pancreatic cancer are diagnosed in Europe and the United States annually
- Pancreatic cancer is a particularly aggressive cancer, with a five-year survival rate of less than 10%. It is currently the fourth most common cause of cancer-related death in the EU
- Pancreatic cancer affect mainly older people. Median age at diagnosis is 70 years
- Approximately 80% of patients treated with chemotherapy, of which approximately 50% will receive second line treatments

Pancreatic cancer and eryaspase

- L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells, from circulating blood plasma. L-asparaginases are well stablished in acute lymphoblastic leukemia (ALL), but their toxicity has limited use in solid tumors
- With eryaspase, the L-asparaginase is encapsulated inside donor-derived red blood cells. The product demonstrated a favorable safety and efficacy profile in different studies in ALL. A Phase 1 study, completed in 2013, also demonstrated a favorable safety profile in pancreatic cancer *(Bachet ea 2015)*
- Asparagine synthetase (ASNS) expression status is believed to play a role in determining sensitivity to asparaginase treatment in several tumor types, such as leukemia, lymphoma and pancreatic cancer.

Phase 2b study design



- N=140 (about 70% ASNS 0/1, 30% ASNS 2/3)
- 2 to 1 randomization (standard of care plus eryaspase versus standard of care alone)
- 16 centers in France
- Study performed with the GERCOR
- Principal investigator: Prof Pascal Hammel, gastroenterologist-oncologist, Head of Oncology Unit at Beaujon Hospital Paris
- IDMC reviewed safety on first 24 patients

erytech

Key study endpoints

- Co-primary endpoints:
  - Progression Free Survival (PFS) and Overall Survival (OS) in ASNS 0/1 patients
  - Positive study if HR <0.85 for either PFS or OS, providing none is >1.0

- Key secondary endpoints:
  - PFS and OS HR in key treatment populations:
    - ASNS 0/1
    - ASNS 2/3
    - Entire population
  - Safety
  - Objective response rate
  - Quality of Life

Primary endpoints met and clear efficacy signal found

- Co-primary endpoints met:
  - PFS in ASNS 0/1+: HR = 0.73
  - OS in ASNS 0/1+: HR = 0.62
- Statistically significant improvement of both PFS and OS across the population
  - OS:
    - HR = 0.57 (p = 0.034) ➔ 43% reduction in risk of death
    - median OS 26.1 (95% CI: 21.0, 28.9) versus 19.0 weeks (95% CI: 12.3, 21.7)
  - Similar results on PFS
- Well balanced baseline and demographic characteristics
- PFS and OS results are consistent and robust across subgroups
- ASNS appears not to be predictive of treatment benefit, but seems to be prognostic. Patients with high ASNS have a worse prognosis
- Treatment is generally well tolerated

Clear survival benefit



erytech

Next steps

- Further review and analysis of data
- Presentation of full dataset at medical meeting
- Publication
- Initiate discussions with FDA and EMA regarding next steps

Key upcoming milestones

- ☑ **Results from Phase 2b pancreatic cancer study**
- ❑ MTD defined in US Phase 1 adult ALL study
- ❑ Meeting with FDA on further ALL development plan
- ❑ Resubmission of EU marketing authorization application for GRASPA in R/R ALL
- ❑ Preclinical proof of concept data with ERYMMUNE and ERYZYME programs
- ❑ Launch of erymethionase (ERY-MET) Phase 1 study
- ❑ **Launch of Phase 3 study in pancreatic cancer**
- ❑ Results from EU Phase 2b AML study

THANK YOU

QUESTIONS?

ERYTECH Pharma SA
60 Avenue Rockefeller
69008 Lyon
France

ERYTECH Pharma Inc
1 Main Street
Cambridge, MA 01242
USA

www.erytech.com

investors@erytech.com